200
Participants
Start Date
July 12, 2023
Primary Completion Date
July 31, 2026
Study Completion Date
July 31, 2026
AZD2936
AZD2936 is a monovalent, bispecific, humanized, IgG1 triple mutant mAb antibody against human PD 1 and TIGIT. AZD2936 was constructed on the backbone of the DuetMab molecule (Mazor et al., 2015), and its antigen binding fragment portions are comprised of the variable domains of the anti TIGIT COM902 antibody and anti PD 1 LO115 antibody. The IgG1 Fc domain carries the triple mutation (L234F/L235E/P331S) designed to reduce Fc mediated immune effector functions. In the preclinical studies, dual blockade of TIGIT and PD 1 by AZD2936 enhanced human T cell function and promoted antitumor immune responses.
RECRUITING
Princess Margaret Cancer Centre, Toronto
Collaborators (2)
AstraZeneca
INDUSTRY
NeoGenomics Laboratories, Inc.
UNKNOWN
University Health Network, Toronto
OTHER